Robert Ilaria
Eli Lilly and Company
26 Papers
106 Citations
Robert Ilaria is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Tasisulam Sodium & Olaratumab. The author has an hindex of 11, co-authored 26 publications. Previous affiliations of Robert Ilaria include University of Texas Southwestern Medical Center & Celgene.
Chat about Author
Papers
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
William D. Tap,William D. Tap,Robin L. Jones,Robin L. Jones,Brian A. Van Tine,Bartosz Chmielowski,Anthony D. Elias,Douglas Adkins,Mark Agulnik,Matthew M. Cooney,Michael B. Livingston,Gregory K. Pennock,Meera Hameed,Gaurav D. Shah,Amy Qin,Ashwin Shahir,Damien M. Cronier,Robert Ilaria,Ilaria Conti,Jan Cosaert,Gary K. Schwartz +20 more
TL;DR: An open-label phase 1b and randomised phase 2 study of doxorubicin plus olaratumab treatment in patients with unresectable or metastatic soft-tissue sarcoma at 16 clinical sites in the USA, finding progression-free survival in phase 2 was 6.6 months and the efficacy was assessed.
572
Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
William P. McGuire,Richard T. Penson,Martin Gore,Antonio Casado Herraez,Patrick Peterson,Ashwin Shahir,Robert Ilaria +6 more
TL;DR: The addition of olaratumab to liposomal doxorubicin did not result in significant prolongation of PFS or OS in platinum-resistant or platinum-refractory ovarian cancer patients.
Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization.
Timothy I. Meier,Mark Uhlik,Sudhakar Chintharlapalli,Michele Dowless,Robert D. Van Horn,Julie Stewart,Wayne Blosser,James A. Cook,Debra A. Young,Xiang S. Ye,Glenn F. Evans,Kelly M. Credille,Darryl Ballard,Lysiane Huber,Andrew Capen,Marcio Chedid,Robert Ilaria,Michele C. Smith,Louis Stancato +18 more
TL;DR: Data show that tasisulam has a unique, dual-faceted mechanism of action involving mitotic catastrophe and antiangiogenesis, a phenotype distinct from conventional chemotherapies and published anticancer agents.
30
A phase 2 study of tasisulam sodium (LY573636 sodium) as second‐line treatment for patients with unresectable or metastatic melanoma
John M. Kirkwood,Rene Gonzalez,Douglas S. Reintgen,Philip Clingan,Robert R. McWilliams,Dinesh P. de Alwis,Annamaria Zimmermann,Michael P. Brown,Robert Ilaria,Michael Millward +9 more
TL;DR: This phase 2 study determined the objective response rate (ORR) in patients who had received 1 previous systemic chemotherapy for unresectable/metastatic melanoma and evaluated the clinical response rate, progression‐free survival (PFS), overall survival (OS), duration of response, safety, and pharmacokinetics.
25
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.
Omid Hamid,Robert Ilaria,Claus Garbe,Pascal Wolter,Michele Maio,Thomas E. Hutson,Ana Arance,Paul Lorigan,Jeeyun Lee,Axel Hauschild,Peter Mohr,Marjo Hahka-Kemppinen,Christopher Kaiser,P. Kellie Turner,Ilaria Conti,Jean-Jacques Grob +15 more
TL;DR: Tasisulam sodium (hereafter referred to as tasisULam) is a novel, highly albumin‐bound agent that demonstrated activity in a phase 2 melanoma study.
22